Skip to content

Released Aug 10, 2022, after the close

10-Q filed Aug 10, 2022, 41 days after period end · 0000950170-22-016443

Q2 2022 · 10-Q
Revenue$896.00K−57.5% vs Q2 2021+262.8% vs Q1 2022
Net Income-$28.70MN/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.87N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$26,080,000N/M
Operating Cash Flowderived-$23,033,000N/M
Margins · derived
Operating margin-2910.7%−2030.3 pt vs Q2 2021
Net margin-3203.1%−2319.9 pt vs Q2 2021

What the release said

The release

Same quarter

MetricQ2 2022Q2 2021Q2 2020Q2 2019
Revenue$896.00K$2.11M$51.00K$67.00K
Net Income-$28.70M-$18.60M-$17.50M-$13.20M
EPS Diluted-$0.87-$0.63-$0.85-$0.74

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR